Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance

Triplet combinations containing a proteasome inhibitor are a standard of care in newly diagnosed multiple myeloma (NDMM). We examined the long-term efficacy and safety of the all-oral combination of weekly ixazomib plus lenalidomide-dexamethasone (IRd), followed by single-agent ixazomib maintenance...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Leukemia
Glavni autori: Kumar, Shaji K., Berdeja, Jesus G., Niesvizky, Ruben, Lonial, Sagar, Laubach, Jacob P., Hamadani, Mehdi, Stewart, A. Keith, Hari, Parameswaran, Roy, Vivek, Vescio, Robert, Kaufman, Jonathan L., Berg, Deborah, Liao, Eileen, Rajkumar, S. Vincent, Richardson, Paul G.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6755968/
https://ncbi.nlm.nih.gov/pubmed/30696949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-019-0384-1
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items